[go: up one dir, main page]

AU2017203184A1 - Carbonic anhydrase inhibitors - Google Patents

Carbonic anhydrase inhibitors Download PDF

Info

Publication number
AU2017203184A1
AU2017203184A1 AU2017203184A AU2017203184A AU2017203184A1 AU 2017203184 A1 AU2017203184 A1 AU 2017203184A1 AU 2017203184 A AU2017203184 A AU 2017203184A AU 2017203184 A AU2017203184 A AU 2017203184A AU 2017203184 A1 AU2017203184 A1 AU 2017203184A1
Authority
AU
Australia
Prior art keywords
optionally substituted
compound
group
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017203184A
Other languages
English (en)
Inventor
Prashant MUJUMDAR
Sally-Ann POULSEN
Chiara RIGANTI
Iris Chiara SALAROGLIO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Griffith University
Original Assignee
Griffith University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Griffith University filed Critical Griffith University
Priority to AU2017203184A priority Critical patent/AU2017203184A1/en
Priority to PCT/AU2018/050443 priority patent/WO2018204987A1/fr
Publication of AU2017203184A1 publication Critical patent/AU2017203184A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/01001—Carbonate dehydratase (4.2.1.1), i.e. carbonic anhydrase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017203184A 2017-05-12 2017-05-12 Carbonic anhydrase inhibitors Abandoned AU2017203184A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2017203184A AU2017203184A1 (en) 2017-05-12 2017-05-12 Carbonic anhydrase inhibitors
PCT/AU2018/050443 WO2018204987A1 (fr) 2017-05-12 2018-05-11 Inhibiteurs d'anhydrase carbonique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2017203184A AU2017203184A1 (en) 2017-05-12 2017-05-12 Carbonic anhydrase inhibitors

Publications (1)

Publication Number Publication Date
AU2017203184A1 true AU2017203184A1 (en) 2018-11-29

Family

ID=64104305

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017203184A Abandoned AU2017203184A1 (en) 2017-05-12 2017-05-12 Carbonic anhydrase inhibitors

Country Status (2)

Country Link
AU (1) AU2017203184A1 (fr)
WO (1) WO2018204987A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115925675B (zh) * 2022-11-10 2025-04-01 中国海洋大学 一种Psammaplin A类衍生物及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19860543A1 (de) * 1998-12-23 2000-06-29 Knoell Hans Forschung Ev Verwendung substituierter Tyrosinderivate als Protease-Inhibitoren

Also Published As

Publication number Publication date
WO2018204987A1 (fr) 2018-11-15

Similar Documents

Publication Publication Date Title
US12310968B2 (en) Chiral diaryl macrocycles and uses thereof
EP2908823B1 (fr) Méthodes de traitement du cancer
EP3572400B1 (fr) Inhibiteur de l'ezh2 et son utilisation
ES2718900T3 (es) Inhibidores de EZH2 humana y métodos de uso de los mismos
EP2817307B1 (fr) Dérivés d'oxazolidin-2-one et leurs utilisations en tant qu'inhibiteurs des pi3ks
Christensen et al. Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure–activity relationship
AU2013343022B2 (en) Oxazolidin-2-one-pyrimidine derivatives
JP2015536308A5 (fr)
EP3271333B1 (fr) Composés inhibiteurs de l'usp7 et leurs procédés d'utilisation
CA3172987A1 (fr) Inhibiteurs a petites molecules de chd1l oncogenes presentant une activite preclinique contre le cancer colorectal
US9572789B2 (en) Methods of treatment using modulators of SIRT2
WO2021136463A1 (fr) Dérivé purine et son utilisation médicale
WO2016081732A1 (fr) Thiénopyrimidines et utilisations de celles-ci
US20220002291A1 (en) Proteolysis-targeting chimeras
US20220153766A1 (en) Condensed tricyclic compound used as kinase inhibitor
Joshi et al. Design and synthesis of topoisomerases-histone deacetylase dual targeted quinoline-bridged hydroxamates as anticancer agents
AU2017203184A1 (en) Carbonic anhydrase inhibitors
US20240239787A1 (en) Compounds for use in the treatment of cancer
EP3442533B1 (fr) Composés inhibiteurs de tg2 et utilisations de ces derniers
US20250115593A1 (en) Rocaglate derivatives and uses thereof
US20220395523A1 (en) Neomycin based compounds, and pharmaceutical use thereof
WO2025101588A1 (fr) Agents de dégradation de bcl-xl hétérobifonctionnels de tétrahydroisoquinoléine
WO2025101571A1 (fr) Agents de dégradation de bcl-x l hétérobifonctionnels de tétrahydroisoquinoléine
HK40031444A (en) Methods of treating cancer
JP2023530734A (ja) アイソフォーム特異的アルデヒドデヒドロゲナーゼ阻害剤

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period